Annovis Bio Inc. (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy buntanetap for neurodegenerative diseases, announced it will host a corporate update webinar on Sept. 2, 2026, at 4 p.m. EDT, followed by a live question-and-answer session. The webinar will feature Founder, President and CEO Maria Maccecchini, Ph.D., who will discuss recent progress, ongoing clinical programs, and upcoming milestones.
The announcement comes as the company prepares for a pivotal year ahead. Annovis has fully enrolled its pivotal Phase 3 Alzheimer's disease (AD) trial, with top-line data and regulatory submissions expected in 2027. This trial is a critical step toward potential approval of buntanetap, which is designed to inhibit the translation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing the underlying causes of neurodegeneration, the drug aims to halt disease progression and improve cognitive and motor functions in patients.
In addition to the Phase 3 AD trial, Annovis plans to begin enrolling patients in an AD open-label study in October 2026 to generate long-term safety data. The company's Parkinson's disease (PD) open-label study is already underway, and discussions are ongoing regarding the initiation of a Parkinson's disease dementia program. These initiatives underscore the company's commitment to expanding its pipeline and addressing unmet medical needs in neurodegenerative diseases.
The webinar is expected to provide investors and stakeholders with a comprehensive overview of the company's progress and strategic direction. Maccecchini will likely elaborate on the design and execution of the Phase 3 trial, the rationale behind the open-label studies, and the potential impact of upcoming data readouts. The live Q&A session will offer an opportunity for participants to engage directly with management.
Annovis Bio, headquartered in Malvern, Pennsylvania, is dedicated to developing treatments for Alzheimer's and Parkinson's diseases. Its lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy that has shown promise in earlier-stage trials. The company's approach targets the production of neurotoxic proteins, which are believed to play a central role in disease progression.
The upcoming webinar is a significant event for the company and the broader neurodegenerative disease community. With the Phase 3 AD trial fully enrolled, the data expected in 2027 could be a pivotal moment for buntanetap. Positive results would not only validate the drug's mechanism but also offer hope to millions of patients worldwide. The open-label studies will provide additional safety and efficacy data, which are crucial for regulatory submissions and eventual commercialization.
Investors and interested parties can access the webinar by visiting the company's website or following the provided link: https://ibn.fm/mls3F. The company also maintains a newsroom for the latest updates: https://ibn.fm/ANVS.
In summary, Annovis Bio's corporate update webinar on Sept. 2, 2026, is a key opportunity for stakeholders to gain insights into the company's clinical programs and milestones. With the Phase 3 AD trial fully enrolled and additional studies in the pipeline, the company is positioning itself for significant advancements in the treatment of Alzheimer's and Parkinson's diseases.
